HUAYAN ROBOTICS (01021) is officially included in the Hong Kong Stock Connect starting today.
Hua Yan Robotics (01021) officially joins the Hong Kong Stock Connect starting today.
HUAYAN ROBOTICS (01021) has officially been included as a constituent stock in the Hong Kong Stock Connect today, allowing mainland investors to buy and sell the stock through the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect. This adjustment was triggered by the quarterly review announced by Hang Seng Indexes Company on August 21, and HUAYAN ROBOTICS has also been included in the Hang Seng Composite Index constituent stocks, with both changes taking effect today.
The company primarily focuses on collaborative Siasun Robot & Automation complete machines and embodied intelligence core motion components, with products covering more than 50 countries and regions, receiving high recognition from numerous leading overseas clients. In the humanoid Siasun Robot & Automation sector, the company has supplied core motion components such as motors and joint modules in bulk to dozens of leading humanoid complete machine enterprises globally.
Furthermore, HUAYAN ROBOTICS recently signed a framework contract with a European humanoid Siasun Robot & Automation company, issuing a procurement order worth up to $100 million over three years. This order includes HUAYAN's collaborative Siasun Robot & Automation complete machines, as well as motors, joint modules, humanoid arms, and wheeled folding Siasun Robot & Automation products developed for humanoid Siasun Robot & Automation.
Related Articles

ONEWO (02602) repurchased 250,000 shares at a cost of approximately HKD 4.7258 million on September 7.

Chongqing Zhifei Biological Products (300122.SZ): The recombinant rotavirus subunit vaccine (Escherichia coli) has obtained approval for clinical trials.

Jiangsu Hengrui Pharmaceuticals (600276.SH) subsidiary SHR-1179 injection has been approved to conduct clinical trials.
ONEWO (02602) repurchased 250,000 shares at a cost of approximately HKD 4.7258 million on September 7.

Chongqing Zhifei Biological Products (300122.SZ): The recombinant rotavirus subunit vaccine (Escherichia coli) has obtained approval for clinical trials.

Jiangsu Hengrui Pharmaceuticals (600276.SH) subsidiary SHR-1179 injection has been approved to conduct clinical trials.

RECOMMEND





